Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β- d -Glucan Synthase: Implication for the Existing Susceptibility Breakpoint
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Thirteen Candida glabrata strains harboring a range of mutations in hot spot regions of FKS1 and FKS2 were studied. The mutations were linked to an echinocandin reduced susceptibility phenotype. Sequence alignments showed that 11 out of the 13 mutants harbored a mutation in FKS1 or FKS2 not previously implicated in echinocandin reduced susceptibility in C. glabrata . A detailed kinetic characterization demonstrated that amino acid substitutions in Fks1p and Fks2p reduced drug sensitivity in mutant 1,3-β- d -glucan synthase by 2 to 3 log orders relative to that in wild-type enzyme. These mutations were also found to reduce the catalytic efficiency of the enzyme ( V max ) and to influence the relative expression of FKS genes. In view of the association of FKS mutations and reduced susceptibility of 1,3-β- d -glucan synthase, an evaluation of the new CLSI echinocandin susceptibility breakpoint was conducted. Only 3 of 13 resistant fks mutants (23%) were considered anidulafungin or micafungin nonsusceptible (MIC > 2 μg/ml) by this criterion. In contrast, most fks mutants (92%) exceeded a MIC of >2 μg/ml with caspofungin. However, when MIC determinations were performed in the presence of 50% serum, all C. glabrata fks mutants showed MICs of ≥2 μg/ml for the three echinocandin drugs. As has been observed with Candida albicans , the kinetic inhibition parameter 50% inhibitory concentration may be a better predictor of FKS -mediated resistance. Finally, the close association between FKS1/FKS2 hot spot mutations provides a basis for understanding echinocandin resistance in C. glabrata .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“C. glabrata may upregulate FKS2 expression to compensate for its decreased catalytic capacity [36]”
From Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata (2012) · cites this paper as [36]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As with azoles, resistance to echinocandin therapy frequently involves mutations in genes encoding the drug target, FKS1 (Candida, Cryptococcus, and Aspergillus spp.) and FKS2 (C. glabrata only)33,34.”
From Molecular mechanisms governing antifungal drug resistance (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“intrinsic genetic, structural, and binding variations in Fks enzymes across Candida species create distinct baseline susceptibilities and predispose certain species to develop heteroresistance under selective pressure from specific echinocandins [51].”
From Calcineurin‐Dependent Stress Adaptation Enables Caspofungin Heteroresistance Leading to Stable Resistance in Candida Glabrata (2026) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, FKS1 point mutations are commonly detected in ECN-resistant (ECN-R) Candida spp. (24, 25).”
From Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris (2022) · cites this paper as [24]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Point mutations in one of two specific hot-spot regions of FKS genes increase the half maximal inhibition concentration (IC50) of an echinocandin in vitro by up to 3 orders of magnitude67.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [67]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics
White, T. J., Bruns, T., Lee, S., & Taylor, J. (1990) · PCR Protocols · doi:10.1016/b978-0-12-372180-8.50042-1 · Cited by 36,648
Self-citationA new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610 · cited 1×
“relative expression levels were evaluated using the Pfaffl method (23).”
MethodPCR protocols — A guide to methods and applications
(1990) · Trends in Genetics · doi:10.1016/0168-9525(90)90186-a · Cited by 11,781
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“glabrata infections are a concern due to their high mortality rates (38) and the tendency of this microorganism to rapidly develop resistance to azole antifungal agents (6, 11, 15, 25, 31, 34).”
BackgroundDenning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“The introduction of the antifungal drug caspofungin (CSF) in 2001 was a significant advance in the treatment of these infections since these lipopeptides’ mode of action is independent of existing antifungal drugs (7, 16, 36).”
BackgroundReference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard
Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,052
Fidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953 · cited 1×
“glabrata infections are a concern due to their high mortality rates (38) and the tendency of this microorganism to rapidly develop resistance to azole antifungal agents (6, 11, 15, 25, 31, 34).”
BackgroundTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Resistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512 · cited 3×
“These IC50s were comparable with previous data obtained for other echinocandin-resistant Candida species strains with FKS mutations (13, 14, 21, 22).”
BackgroundResultSelf-citationPark, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Self-citation
Cited by
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Self-citationPfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
“5 μg/mL) would be more sensitive in detecting strains with FKS1/FKS2 mutations [5, 6, 25].”
BackgroundMethodSelf-citationMechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
“(Garcia-Effron et al. 2009a).”
BackgroundInfluentialSelf-citationDrug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Kathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00367-15 · Cited by 532
“auris isolates by sequence homology (21, 22).”
Antifungal resistance: current trends and future strategies to combat
Wiederhold, N. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s124918 · Cited by 468
Pfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484
“These mutations, which result in elevated MICs (4-to-30-fold MIC increases for caspofungin and 90-to-110-fold increases for anidulafungin and micafungin), reduce the sensitivity of GS to drug inhibition by 30- to 1,000-fold (28, 29).”
BackgroundAntifungal Therapy: New Advances in the Understanding and Treatment of Mycosis
Scorzoni, L., de Paula e Silva, A. C. A., Marcos, C. M., Assato, P. A., de Melo, W. C. M. A., de Oliveira, H. C., Costa-Orlandi, C. B., Mendes-Giannini, M. J. S., & Fusco-Almeida, A. M. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00036 · Cited by 418
“…alterations in FKS1 in other Candida species (Park et al., 2005; Desnos-Ollivier et al., 2008; Garcia-Effron et al., 2008, 2010), whereas mutations in Fks1 and its paralog Fks2 have been associated with resistance in C. glabrata (Garcia-Effron et al., 2009; Pham et al., 2014; Perlin, 2015).”
BackgroundAntifungal drug resistance among Candida species: mechanisms and clinical impact
Sanguinetti, M., Posteraro, B., & Lass‐Flörl, C. (2015) · Mycoses · doi:10.1111/myc.12330 · Cited by 394
Pfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377
Echinocandin resistance in Candida.
Perlin, D. S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ791 · Cited by 374
“amino acid substitutions can decrease the sensitivity of glucan synthase by several log orders [13, 16], resulting in elevated minimum inhibitory concentration (MIC) values.”
Self-citationEchinocandin Antifungal Drugs in Fungal Infections: A Comparison
Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371
“5 mg/mL) may be more sensitive for detection of strains with FKS mutations and that ‘susceptibility’ breakpoints of £2 ug/mL may be too high for anidulafungin and micafungin.([27,40]) Studies defining the MIC distribution of wild-typeCandida strains to establish epidemiological cutoff values (ECVs) for susceptibility…”
BackgroundMethodThe Candida Pathogenic Species Complex
Turner, S. A., & Butler, G. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019778 · Cited by 336
“Resistance to echinocandins is associated with mutations in the FKS1 and FKS2 genes (Garcia-Effron et al. 2009; Alexander et al. 2013).”
BackgroundPfaller, M. A., Diekema, D. J., Andes, D., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M., & Perlin, D. S. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.004 · Cited by 334
Self-citationMechanisms of echinocandin antifungal drug resistance
Perlin, D. S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12831 · Cited by 313
Self-citationEchinocandins – structure, mechanism of action and use in antifungal therapy
Szymański, M., Chmielewska, S., Czyżewska, U., Malinowska, M., & Tylicki, A. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2050224 · Cited by 270
Molecular mechanisms governing antifungal drug resistance
Lee, Y., Robbins, N., & Cowen, L. E. (2023) · npj Antimicrobials and Resistance · doi:10.1038/s44259-023-00007-2 · Cited by 304
“As with azoles, resistance to echinocandin therapy frequently involves mutations in genes encoding the drug target, FKS1 ( Candida, Cryptococcus , and Aspergillus spp.) and FKS2 ( C. glabrata only) 33,34 .”
Virulence Factors in Candida species
Staniszewska, M. (2020) · Current Protein & Peptide Science · doi:10.2174/1389203720666190722152415 · Cited by 279
Healey, K. R., Zhao, Y., Perez, W. B., Lockhart, S. R., Sobel, J. D., Farmakiotis, D., Kontoyiannis, D. P., Sanglard, D., Taj-Aldeen, S. J., Alexander, B. D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11128 · Cited by 276
Self-citationCurrent Perspectives on Echinocandin Class Drugs
Perlin, D. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.19 · Cited by 274
“In C. glabrata, FKS1 and FKS2 are major sources of resistance.”
BackgroundInfluentialSelf-citationFungal echinocandin resistance
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267
Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris
Kordalewska, M., Lee, A., Park, S., Berrio, I., Chowdhary, A., Zhao, Y., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00238-18 · Cited by 247
“albicans) cause the most pronounced resistance phenotypes (34, 37, 38).”
BackgroundSelf-citationGenomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris
Rhodes, J., Abdolrasouli, A., Farrer, R. A., Cuomo, C. A., Aanensen, D. M., Armstrong-James, D., Fisher, M. C., & Schelenz, S. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0045-x · Cited by 246
Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens
Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230
“glabrata reduces susceptibility to a lesser degree [42,107,108].”
BackgroundCosta-de-Oliveira, S., & Rodrigues, A. G. (2020) · Microorganisms · doi:10.3390/microorganisms8020154 · Cited by 229
“Such fact suggests that caspofungin could be less potent than the other two drugs [86,90].”
BackgroundIslam, T., Danishuddin, Tamanna, N. T., Matin, M. N., Barai, H. R., & Haque, M. A. (2024) · Plants · doi:10.3390/plants13192737 · Cited by 186
“Similarly, mutations in the genes encoding the therapeutic targets FKS1 ( Candida , Cryptococcus , and Aspergillus species) and FKS2 ( C. glabrata alone) are often responsible for resistance to echinocandin therapy [89,90].”
BackgroundEspinel-Ingroff, A., Arendrup, M. C., Pfaller, M. A., Bonfietti, L. X., Bustamante, B., Canton, E., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Fothergill, A., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01519-13 · Cited by 216
Elevated Chitin Content Reduces the Susceptibility of Candida Species to Caspofungin
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01486-12 · Cited by 214
“glabrata, resistance-conferring point mutations have also been identified in FKS2 that result in amino acid substitutions at positions 659 to 666 and 1375 (23).”
BackgroundCarolus, H., Pierson, S., Muñoz, J. F., Subotić, A., Cruz, R. B., Cuomo, C. A., & Van Dijck, P. (2021) · mBio · doi:10.1128/mbio.03333-20 · Cited by 211
“albicansa 641 F L T L S L R D P 692 L D T Y M W Y I I C N 1358 W I R R 3(77) L3 P3 G5 Y3 H3 H3 4(78) S3 Y3 L5 G6 5(79) Y4 F3 6(80)”
Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin Resistance In Vivo
Lee, K. K., MacCallum, D. M., Jacobsen, M. D., Walker, L. A., Odds, F. C., Gow, N. A. R., & Munro, C. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00683-11 · Cited by 209
“glabrata can also lead to reduced susceptibility to the echinocandins (23).”
BackgroundGlobal Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata
Singh-Babak, S. D., Babak, T., Diezmann, S., Hill, J. A., Xie, J. L., Chen, Y.-L., Poutanen, S. M., Rennie, R. P., Heitman, J., & Cowen, L. E. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002718 · Cited by 205
Update on Antifungal Drug Resistance
Perlin, D. S., Shor, E., & Zhao, Y. (2015) · Current Clinical Microbiology Reports · doi:10.1007/s40588-015-0015-1 · Cited by 174
Self-citationMolecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species
Czajka, K. M., Venkataraman, K., Brabant-Kirwan, D., Santi, S. A., Verschoor, C., Appanna, V. D., Singh, R., Saunders, D. P., & Tharmalingam, S. (2023) · Cells · doi:10.3390/cells12222655 · Cited by 180
FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Beyda, N. D., John, J., Kilic, A., Alam, M. J., Lasco, T. M., & Garey, K. W. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu407 · Cited by 174
“In vitro studies have shown that the level of glucan synthase enzyme inhibition varies depending on the specific FKS gene mutation, resulting in isolates with differing elevations in echinocandin MICs [5].”
Shields, R. K., Nguyen, M. H., Press, E. G., Kwa, A. L., Cheng, S., Du, C., & Clancy, C. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00027-12 · Cited by 171
“In C. glabrata, -1,3-D-glucan synthase is encoded by three related genes (FKS1, FKS2, and FKS3) (15).”
BackgroundMethodInfluentialEspinel-Ingroff, A., Cuenca-Estrella, M., Fothergill, A., Fuller, J., Ghannoum, M., Johnson, E., Pelaez, T., Pfaller, M. A., & Turnidge, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00686-11 · Cited by 164
Arendrup, M. C., Garcia-Effron, G., Lass-Flörl, C., Lopez, A. G., Rodriguez-Tudela, J.-L., Cuenca-Estrella, M., & Perlin, D. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01256-09 · Cited by 158
“glabrata isolates with resistance mutants not separating very well from the wild-type population (17, 45).”
BackgroundSelf-citationWild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp
Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., Jones, R. N., Turnidge, J., & Diekema, D. J. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01590-09 · Cited by 154
“5 g/ml may be more sensitive in detecting those strains with FKS1 mutations (7, 8).”
BackgroundA comprehensive overview of the medicinal chemistry of antifungal drugs: perspectives and promise
Howard, K. C., Dennis, E. K., Watt, D. S., & Garneau-Tsodikova, S. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00556k · Cited by 140
Katiyar, S. K., Alastruey-Izquierdo, A., Healey, K. R., Johnson, M. E., Perlin, D. S., & Edlind, T. D. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00813-12 · Cited by 148
“(16) and 20409 (24) clinical isolates were previously described, and their MICs were”
BackgroundMethodSelf-citationEchinocandins in antifungal pharmacotherapy
Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145
De Carolis, E., Vella, A., Florio, A. R., Posteraro, P., Perlin, D. S., Sanguinetti, M., & Posteraro, B. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00224-12 · Cited by 140
“and 8 g/ml, respectively) having the lowest MPCC value (2 g/ ml) did not harbor mutations at Ser629 (Fks1) or Ser663 (Fks2), which were indeed seen to display the highest 50% inhibitory concentration (IC50) values for all echinocandin drugs (12).”
BackgroundMethodSelf-citationPortrait of Candida Species Biofilm Regulatory Network Genes
Araújo, D., Henriques, M., & Silva, S. M. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.09.004 · Cited by 157
Expandable and reversible copy number amplification drives rapid adaptation to antifungal drugs
Todd, R. T., & Selmecki, A. (2020) · eLife · doi:10.7554/elife.58349 · Cited by 138
“…are found in drug-resistant isolates of C. albicans and interestingly, are recurrent in distantly related Candida species as well, including C. glabrata and C. auris (Flowers et al., 2015; Garcia-Effron et al., 2009; Hope et al., 2004; Morschhäuser et al., 2007; Muñoz et al., 2018; Perlin, 2011).”
BackgroundGarcía‐Effrón, G. (2020) · Journal of Fungi · doi:10.3390/jof6040262 · Cited by 143
“A second function of Rho1p is to sense stress signals due to 1,3-β-D-glucan depletion and to activate as a response a wide variety of effectors ranging from protein kinase C, SLT2 [44], calcineurin/CRZ1/Ca2+, and HOG [54,55] to Hsp90p, Mkc1p, and Sgt1p [46,56–59].”
BackgroundZimbeck, A. J., Iqbal, N., Ahlquist, A. M., Farley, M. M., Harrison, L. H., Chiller, T., & Lockhart, S. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00836-10 · Cited by 136
“glabrata clinical isolates with FKS mutations, the majority of the isolates (69%) had mutations in FKS2 (15).”
BackgroundInfluentialGuinea, J., Zaragoza, Ó., Escribano, P., Martín-Mazuelos, E., Pemán, J., Sánchez-Reus, F., & Cuenca-Estrella, M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02155-13 · Cited by 131
Beardsley, J., Halliday, C. L., Chen, S. C.-A., & Sorrell, T. C. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0059 · Cited by 124
Pfaller, M. A., Castanheira, M., Diekema, D. J., Messer, S. A., Moet, G. J., & Jones, R. N. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02445-09 · Cited by 128
Candida glabrata Biofilms: How Far Have We Come?
Rodrigues, C., Rodrigues, M., Silva, S., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010011 · Cited by 129
Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
Jallow, S., & Govender, N. P. (2021) · Journal of Fungi · doi:10.3390/jof7030163 · Cited by 129
“Resistance to echinocandins is due to mutations in the FKS genes, encoding for the catalytic site of the β-(1,3) D-glucan synthase enzyme complex; specifically, mutations in two areas designated as hot spots 1 and 2 [32,33], have been associated with reduced susceptibility to echinocandins [33,34].”
BackgroundArendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. W. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2014.01.001 · Cited by 129
Current status of antifungal resistance and its impact on clinical practice
Alcazar‐Fuoli, L., & Mellado, E. (2014) · British Journal of Haematology · doi:10.1111/bjh.12896 · Cited by 117
“…therapy has been associated with amino acid substitutions in FKS1 (C. albicans, C. tropicalis, C. krusei, C. glabrata, C. lusitaniae) (Park et al, 2005; Garcia-Effron et al, 2009; Desnos-Ollivier et al, 2011; Jensen et al, 2013) and FKS2 (C. glabrata) (Garcia-Effron et al, 2009; Lewis et al, 2013).”
Jiménez-Ortigosa, C., Paderu, P., Motyl, M. R., & Perlin, D. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02145-13 · Cited by 122
“fumigatus (1 WT strain and 1 fks mutant strain), as described previously (18, 19).”
MethodSelf-citationArendrup, M. C., Perlin, D. S., Jensen, R. H., Howard, S. J., Goodwin, J., & Hope, W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06369-11 · Cited by 117
“This has been demonstrated at the enzyme level and by broth microdilution and disk diffusion testing (5, 21, 22).”
MethodSelf-citationEchinocandins: production and applications
Emri, T., Majoros, L., Tóth, V., & Pócsi, I. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-4761-9 · Cited by 126
“Other species (e.g. C. parapsilosis, C. lusitaniae and C. guilliermondii) show higher MIC values to echinocandins in RPMI-1640 as test medium which is explained by their naturally occurring Fks1 polymorphisms (see below) (Chen et al. 2011; Garcia-Effron et al. 2008; Pfaller et al. 2009, 2011b; Perlin et al. 2007).”
BackgroundInfluentialResistance to Antifungal Drugs
Ben‐Ami, R., & Kontoyiannis, D. P. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.003 · Cited by 122
Beyda, N. D., Lewis, R. E., & Garey, K. W. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r020 · Cited by 109
Fungal Drug Response and Antimicrobial Resistance
Osset-Trénor, P., Pascual‐Ahuir, A., & Proft, M. (2023) · Journal of Fungi · doi:10.3390/jof9050565 · Cited by 119
“glabrata, modifications at S663 in Fks2, S629 in Fks1, and F659 in Fks2 are the most prominent substitutions [176,177].”
BackgroundChapeland-Leclerc, F., Hennequin, C., Papon, N., Noël, T., Girard, A., Socié, G., Ribaud, P., & Lacroix, C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01138-09 · Cited by 104
Shields, R. K., Nguyen, M. H., Press, E. G., Updike, C. L., & Clancy, C. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00136-13 · Cited by 105
“Hot spots 1 and 2 of FKS1 and FKS2 were amplified using PCR as previously described (4, 20).”
MethodLewis, J. S., Wiederhold, N. P., Wickes, B. L., Patterson, T. F., & Jorgensen, J. H. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01144-13 · Cited by 101
Posteraro, B., Torelli, R., Vella, A., Leone, P. M., Angelis, G. D., Carolis, E. D., Ventura, G., Sanguinetti, M., & Fantoni, M. (2020) · Journal of Fungi · doi:10.3390/jof6030163 · Cited by 108
Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management
Perlin, D. S. (2014) · Drugs · doi:10.1007/s40265-014-0286-5 · Cited by 99
“albicans confer reduced fitness [25, 26, 81], since they can decrease the catalytic reaction rate maximum for glucan biosynthesis [26, 45] and alter cell wall morphology [81].”
InfluentialSelf-citationEspinel-Ingroff, A., Fothergill, A., Fuller, J., Johnson, E., Pelaez, T., & Turnidge, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01730-10 · Cited by 95
“clinical strains have been associated with genetic mutations conferring amino acid substitutions in the FKS1 and FKS2 gene products, therapeutic failure, and/or breakthrough infection (5, 10, 17, 18, 26, 28).”
BackgroundJohnson, M. E., Katiyar, S. K., & Edlind, T. D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01811-10 · Cited by 91
“fer relatively uniform echinocandin cross-RES (2, 11, 27) and,”
BackgroundParente-Rocha, J. A., Bailão, A. M., Amaral, A. C., Taborda, C. P., Paccez, J. D., Borges, C. L., & Pereira, M. (2017) · Mediators of Inflammation · doi:10.1155/2017/9870679 · Cited by 94
“For the FKS2 subunit, the substitutions Ser641 and Ser645 strongly reduce enzyme activity, causing a pronounced resistance phenotype [20, 31].”
BackgroundAntifungal Resistance in Candida auris: Molecular Determinants
Frías-De-León, M. G., Hernández-Castro, R., Vite-Garín, T., Arenas, R., Bonifaz, A., Castañón-Olivares, L., Acosta-Altamirano, G., & Martínez-Herrera, E. (2020) · Antibiotics · doi:10.3390/antibiotics9090568 · Cited by 93
Jiménez-Ortigosa, C., Perez, W. B., Angulo, D., Borroto-Esoda, K., & Perlin, D. S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00833-17 · Cited by 89
“Productentrapped -(1,3)-D-glucan synthase complexes were extracted as described previously (10).”
BackgroundMethodSelf-citationDrug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis
Murphy, S. E., & Bicanic, T. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.759408 · Cited by 83
Antifungal drug resistance: do molecular methods provide a way forward?
Perlin, D. S. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283321ce5 · Cited by 89
Self-citationFormosa, C., Schiavone, M., Martin-Yken, H., François, J. M., Duval, R. E., & Dague, E. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00105-13 · Cited by 85
Mutational Analysis of Flucytosine Resistance in Candida glabrata
Edlind, T. D., & Katiyar, S. K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00605-10 · Cited by 83
“However, in contrast to echinocandin resistance, which requires specific Fks1 hot spot mutations that minimally affect enzymatic activity (6), the data presented here and previously suggest that high-level 5FC resistance is conferred by a wide array of mutations conferring null phenotypes for Fcy1 or Fur1.”
BackgroundSpettel, K., Barousch, W., Makristathis, A., Zeller, I., Nehr, M., Selitsch, B., Lackner, M., Rath, P.-M., Steinmann, J., & Willinger, B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210397 · Cited by 86
Antifungal Susceptibility Testing: A Primer for Clinicians
Wiederhold, N. P. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab444 · Cited by 90
“For the echinocandins, point mutations within highly conserved regions (hot spots) of the genes (ie, FKS1 and FKS2) that encode the (1,3)-d-glucan synthase enzyme can cause resistance [171, 172].”
BackgroundCD101: a novel long-acting echinocandin
Zhao, Y., Perez, W. B., Jiménez‐Ortigosa, C., Hough, G., Locke, J. B., Ong, V., Bartizal, K., & Perlin, D. S. (2016) · Cellular Microbiology · doi:10.1111/cmi.12640 · Cited by 81
“…isolate showed the typical pattern of β-1,3-D-glucan synthase echinocandin susceptibility reported with other sensitive Candida species (Park et al., 2005; Garcia-Effron et al., 2009), with mean IC50s of 17.7 and 14.3 ng/ml for MCF and CD101, respectively (supplementary figure and Table 2).”
BackgroundMethodSelf-citationClinical perspectives on echinocandin resistance among Candida species
Shields, R. K., Nguyen, M. H., & Clancy, C. J. (2015) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000215 · Cited by 76
Antifungal drug resistance in Candida species
Morace, G., Perdoni, F., & Borghi, E. (2014) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2014.09.002 · Cited by 80
CRS–MIS in Candida glabrata: sphingolipids modulate echinocandin–Fks interaction
Healey, K. R., Katiyar, S. K., Raj, S., & Edlind, T. D. (2012) · Molecular Microbiology · doi:10.1111/j.1365-2958.2012.08194.x · Cited by 79
“…isolates), are strictly associated with mutations in b-1,3glucan synthase genes FKS1 and FKS2, and typically exhibit CSF, MCF and ANF cross-resistance (Katiyar et al., 2006; Cleary et al., 2008; Garcia-Effron et al., 2009; Castanheira et al., 2010; Pfeiffer et al., 2010; Zimbeck et al., 2010).”
InfluentialPfaller, M. A., Chaturvedi, V. P., Diekema, D. J., Ghannoum, M. A., Holliday, N. M., Killian, S. B., Knapp, C. C., Messer, S. A., Miskou, A., & Ramani, R. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.05.008 · Cited by 76
“…discriminating wild-type (WT) strains of Candida (lack acquired or mutational resistance mechanisms) from non-WT strains (possess mutational fks resistance mechanisms) (Arendrup et al., 2010; Castanheira et al., 2010; Garcia-Effron et al., 2009; Pfaller et al., 2010b, 2011; Zimbeck et al., 2010).”
BackgroundSchell, W. A., Jones, A. M., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., & Alexander, B. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01817-16 · Cited by 74
“glabrata isolates were screened for FKS gene mutations as previously described (13).”
MethodPfaller, M. A., Messer, S. A., Diekema, D. J., Jones, R. N., & Castanheira, M. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02481-13 · Cited by 74
“, these results provide strong support for concerns regarding the issue of crossresistance between micafungin and caspofungin (5, 15, 16, 18, 22, 26).”
ResultRecent Insights into the Paradoxical Effect of Echinocandins
Wagener, J., & Loiko, V. (2017) · Journal of Fungi · doi:10.3390/jof4010005 · Cited by 73
Jiménez-Ortigosa, C., Moore, C., Denning, D. W., & Perlin, D. S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01277-17 · Cited by 72
Self-citationRapid Development of Candida krusei Echinocandin Resistance during Caspofungin Therapy
Forastiero, A., Garcia-Gil, V., Rivero-Menendez, O., Garcia-Rubio, R., Monteiro, M. C., Alastruey-Izquierdo, A., Jordan, R., Agorio, I., & Mellado, E. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01005-15 · Cited by 68
Sun, H., & Singh, N. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.09.020 · Cited by 74
Pfaller, M. A., Rhomberg, P. R., Messer, S. A., & Castanheira, M. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.11.008 · Cited by 67
Arendrup, M. C., Pfaller, M. A., & the Danish Fungaemia Study Group (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00355-12 · Cited by 67
Locke, J. B., Almaguer, A. L., Zuill, D. E., & Bartizal, K. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00620-16 · Cited by 64
Schell, W. A., Jones, A. M., Borroto-Esoda, K., & Alexander, B. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-17 · Cited by 66
Castanheira, M., Messer, S. A., Jones, R. N., Farrell, D. J., & Pfaller, M. A. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.06.007 · Cited by 66
Pathogenesis and Antifungal Drug Resistance of the Human Fungal Pathogen Candida glabrata
Tscherner, M., Schwarzmüller, T., & Kuchler, K. (2011) · Pharmaceuticals · doi:10.3390/ph4010169 · Cited by 59
“CDR1, CDR2, SNQ2 Reduced azole resistance [25,26] FKS1, FKS2 Mutations lead to echinocandin resistance [27,28,29,30]”
BackgroundShields, R. K., Nguyen, M. H., Du, C., Press, E., Cheng, S., & Clancy, C. J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00999-10 · Cited by 65
Satish, S., Jiménez-Ortigosa, C., Zhao, Y., Lee, M. H., Dolgov, E., Krüger, T., Park, S., Denning, D. W., Kniemeyer, O., Brakhage, A. A., et al. (2019) · mBio · doi:10.1128/mbio.00779-19 · Cited by 64
“These mutations decrease the sensitivity of the enzyme to echinocandins by up to 3,000-fold (21, 25, 26).”
BackgroundSelf-citationMedically Important Fungi Respond to Azole Drugs: An Update
Zavřel, M., & White, T. C. (2015) · Future Microbiology · doi:10.2217/fmb.15.47 · Cited by 69
Ning, Y., Xiao, M., Perlin, D. S., Zhao, Y., Lu, M., Li, Y., Luo, Z., Dai, R., Li, S., Xu, J., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2153086 · Cited by 63
“Similarly, the homologous mutation S629 of Fks2 confers the highest MICs in C. glabrata [15,56].”
Self-citationBizerra, F. C., Jimenez-Ortigosa, C., Souza, A. C. R., Breda, G. L., Queiroz-Telles, F., Perlin, D. S., & Colombo, A. L. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02189-13 · Cited by 63
“We performed an in vitro glucan synthase inhibition assay, as previously described (17, 18, 19).”
MethodSelf-citationPfaller, M., Boyken, L., Hollis, R., Kroeger, J., Messer, S., Tendolkar, S., & Diekema, D. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02120-10 · Cited by 59
Metadata
- Authors
- Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S.
- Affiliations
- Public Health Research Institute, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey 07103
- University of New Mexico (US)
- Rutgers New Jersey Medical School (US)
- University of Mississippi (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-09
- Volume
- 53
- Issue
- 9
- Pages
- 3690-3699
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2737881
- OpenAlex
- W2163061527
- Cited by
- 323
- References
- 40
- Citations by year
- 2026: 18 · 2025: 12 · 2024: 12 · 2023: 14 · 2022: 10 · 2021: 17 · 2020: 22 · 2019: 18 · 2018: 20 · 2017: 26 · 2016: 14 · 2015: 17 · 2014: 25 · 2013: 16 · 2012: 26
- FWCI
- 18.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (AI069397, R01AI069397)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida glabrata, echinocandin resistance, 1,3-β-D-glucan synthase, FKS1, FKS2, hot spot mutations, anidulafungin, micafungin, caspofungin, susceptibility breakpoints, enzyme kinetics, catalytic efficiency, antifungal resistance
- MeSH terms
- Antifungal Agents, Fungal Proteins, Glucosyltransferases, Reverse Transcriptase Polymerase Chain Reaction, Drug Resistance, Fungal, Candida glabrata, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.